Results 331 to 340 of about 3,321,902 (364)

Antibacterial Agents in Dermatology

2000
The contemporary dermatologist quite often confronts bacterial skin and/or soft tissue infections. Therefore he should be familiar with antibacterial agents, particularly with newer antibiotics and their role in modern chemotherapy. Classification of cutaneous infections on morphologic and clinical criteria are helpful in providing initial clues ...
openaire   +2 more sources

A multi-agent architecture for teaching dermatology

Medical Informatics, 1998
This work proposes the integration of computer-aided instruction systems in the curricula of medical education, and describes an intelligent tutoring system used for teaching Dermatology. The Dermatology Tutor uses a self-organized society of autonomous software agents which have different capabilities or roles.
Ioannis D. Zaharakis, Achilles Kameas, G. C. Nikiforidis   +2 more
openaire   +3 more sources

Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management.

Seminars in Oncology, 2015
Targeted treatments have distinctive side effects: dermatologic problems (rash, hand-food skin reaction, skin/hair whitening), endocrine dysfunction (hyperglycemia, hypothyroidism, dyslipidemia), as well as hypertension, diarrhea, liver problems, ocular ...
Sariah Liu, R. Kurzrock
semanticscholar   +1 more source

Keratinolytic Agents in Dermatology

1990
Keratin is an essential constituent of the keratin laminae which, together with the intercellular substances in the skin, form the stratum corneum with its barrier function and give the hair and nails their physical properties.
openaire   +2 more sources

Biological Agents in Pediatric Dermatology

2017
Biological agents are revolutionizing the treatment of immune-mediated disease across many disciplines, including rheumatology, gastroenterology, and dermatology. For children with psoriasis, these medications represent a welcome alternative to broad immunosuppressants such as methotrexate and cyclosporine when topical therapies are inadequate.
Emily B. Lund, Amy S. Paller
openaire   +2 more sources

Targeted Agents: Management of Dermatologic Toxicities [PDF]

Journal of the National Comprehensive Cancer Network, 2014
Epidermal growth factor receptor (EGFR) inhibitors are widely used in the treatment of many cancers, and the cutaneous toxicity profile associated with these agents has become prominent. In fact, dermatologic side effects have also been reported with other targeted agents, including both BRAF and mTOR inhibitors.
openaire   +2 more sources

The Use and Abuse of Immunosuppressive Agents in Dermatology

Archives of Dermatology, 1985
In this issue of theArchives, Paslin 1 describes three patients in whom a remission of lichen planus occurred as a consequence of short-term cyclophosphamide therapy. It was obviously a small, open-label drug trial, and therefore, it should be interpreted carefully.
Ira Bell, Gerald D. Weinstein
openaire   +3 more sources

New Dermatological Agents for the Treatment of Psoriasis

Journal of Medicinal Chemistry, 2001
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Roshantha A.S. Chandraratna, Sunil Nagpal, Kwok-Yin Tsang, Scott M. Thacher, Jayasree Vasudevan   +4 more
openaire   +4 more sources

Cytotoxic agents for use in dermatology. I

Journal of the American Academy of Dermatology, 1985
There are indications for the use of cytotoxic drugs in some dermatologic diseases. These drugs may be lifesaving for patients with diseases such as pemphigus, lymphomas, and vasculitis or they may merely offer an improved quality of life for patients who have diseases such as psoriasis, progressive systemic sclerosis, or sarcoidosis.
openaire   +3 more sources

Overview of biologic agents in medicine and dermatology

Seminars in Cutaneous Medicine and Surgery, 2005
Three agents have recently been approved by the Food and Drug Administration for the treatment of chronic plaque psoriasis: alefacept, efalizumab, and etanercept. The field of dermatology has now entered a new era, joining other disciplines of medicine that have been using biologic agents for decades.
openaire   +3 more sources